Cytokinetics, a cardiovascular biopharmaceutical company, granted stock options for 60,465 shares and 40,084 restricted stock units (RSUs) to 29 new employees hired in September and October 2026. The RSUs vest over three years, while the stock options vest over four years with a $63.92 exercise price, matching the stock's closing price on the grant date. These grants serve as inducements to employment under Nasdaq Listing Rule 5635(c)(4). Cytokinetics continues to develop treatments for heart conditions, including its approved drug MYQORZO® and investigational therapies for heart failure.
Cytokinetics' recent inducement grants highlight its ongoing efforts to attract talent in the competitive biopharmaceutical sector. On Pluang, CYTK shares are trading at USD 62.41, up 0.74% as of Oct 20, 2026 03:11 WIB, below its 52-week high of USD 87.26. The stock's market cap stands at $8.62 billion, reflecting steady investor interest in its cardiovascular treatments and pipeline.
